Christian S. Hinrichs, M.D.
Dr. Hinrichs researches immunotherapy for HPV+ cancers, which include cervical, oropharyngeal, anal, vulvar, vaginal, and penile malignancies. He has discovered personalized cellular and gene therapies for HPV+ cancers. His laboratory is studying why these treatments work in some patients and not in others and is using what is learned to innovate more effective therapies.
Open - RecruitingNCI Protocol ID NCI-19-C-0002Investigator Christian S. Hinrichs, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Erin Ferraro 240.760.6163
A Phase I Study of Immunotherapy with E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial LesionsOpen - RecruitingNCI Protocol ID NCI-17-C-0116Investigator Christian S. Hinrichs, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Erin Ferraro 240-760-6163
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 with or without PD-1 Blockade for HPV-Associated CancersOpen - RecruitingNCI Protocol ID NCI-16-C-0154Investigator Christian S. Hinrichs, M.D.
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell TherapyOpen - RecruitingNCI Protocol ID NCI-16-C-0138Investigator Christian S. Hinrichs, M.D.
Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy ProtocolsOpen - RecruitingNCI Protocol ID NCI-16-C-0061Investigator Christian S. Hinrichs, M.D.
Cellular Therapy for Cancer
Dr. Hinrichs conducts basic and clinical research to discover and develop novel T cell therapies for the treatment of patients with cancer. This work includes a clinical trial of HPV-targeted tumor-infiltrating T cells for patients with HPV+ cancers, which has demonstrated that this treatment can mediate complete regression of cervical cancer in some patients. Dr. Hinrichs' laboratory also has discovered genes for T cell receptors that target HPV, and his group is testing new gene therapy treatments based on these receptors for patients with advanced HPV+ tumors.
Selected Recent Publications
Complete regression of metastatic cervical cancer following treatment with human papillomavirus-targeted tumor-infiltrating T cells.J Clin Oncol. 33(14): 1543-50, 2015. [ Journal Article ]
- Clin Cancer Res. 21(19): 4431-9, 2015. [ Journal Article ]
- Science. 344(6184): 641-5, 2014. [ Journal Article ]
- Immunol Rev. 257(1): 56-71, 2014. [ Journal Article ]
- Nat Biotechnol. 31(11): 999-1008, 2013. [ Journal Article ]
Dr. Hinrichs received his B.A. and M.D. degrees from the combined 6-year program at the University of Missouri - Kansas City (UMKC). He trained in general surgery at UMKC and in surgical oncology at Roswell Park Cancer Institute. He then completed a surgical oncology and tumor immunology fellowship at the Surgery Branch of the National Cancer Institute (NCI). Subsequently he trained in internal medicine at George Washington University and in medical oncology at the Medical Oncology Branch of the NCI. Dr. Hinrichs conducts basic research and clinical research to develop T-cell therapies for cancers caused by human papillomaviruses.
|Position||Keywords||Number of Positions||Contact E-mail||Contact Name|
tumor immunology, CAR-T, T cell, vaccine, checkpoint
|Multiple Positions Availablefirstname.lastname@example.org||Carylinda Serna|
|Benjamin Clark||Biologist (Contr.)|
|John Davies Ph.D.||Postdoctoral Fellow (CRTA)|
|Stacey Doran M.D.||Clinical Fellow|
|Lindsey Draper M.D.||Postdoctoral Fellow (CRTA)|
|Vicki Fellows M.T. (ASCP)||Biologist|
|Erin Ferraro||Research Nurse Coordinator|
|Nikolaos Gkitsas||Biologist (Contr)|
|Benjamin Jin Ph.D.||Biologist (Contr)|
|Jae Ho Kim B.S.||Postbaccalaureate Fellow (CRTA)|
|Bridget Marcinkowski B.S.||Postbaccalaureate Fellow (CRTA)|
|Rachael Mohn||Patient Care Coordinator (Contr)|
|Nisha Nagarsheth Ph.D.||Postdoctoral Fellow (CRTA)|
|Carylinda Serna||Biologist (Contr)|
|Andrew Sinkoe Ph.D.||Postdoctoral Fellow (CRTA)|
|Ling (Lisa) Zhang Ph.D.||Biologist|